secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001628280-23-030137
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q2 net loss $0.10/share; cash at $70.6M; INDs cleared for two gene therapies
--------------------------------------------------------------------------------

- Cash, cash equivalents & investments $70.6M at June 30, 2023, down from $90.9M at Dec 31, 2022.
- Net loss per share $0.10 for Q2 2023 vs $0.09 a year ago; includes $4.4M non-cash impairment on COVAXIN supply asset.
- Operating expenses $23.7M (R&D $14.2M, G&A $9.6M); R&D includes $4.4M impairment and disposal loss.
- FDA cleared INDs for OCU410 (geographic atrophy) and OCU410ST (Stargardt disease); Phase 1/2 trials planned by year-end.
- OCU400 Phase 3 trial expected to begin late 2023/early 2024; updated Phase 1/2 results due this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828023030137/0001628280-23-030137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828023030137/ocgn-20230821.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-030137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer